Clinical Characteristics and Risk Factors of COVID-19 in 60 Adult Cancer Patients.
COVID-19
Risk factor
hematologic neoplasms
malignant neoplasms
mortality
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
08
2021
accepted:
22
12
2021
entrez:
3
2
2022
pubmed:
4
2
2022
medline:
4
2
2022
Statut:
epublish
Résumé
During the pandemic of COVID-19, cancer patients have been considered as one high-risk group in the morbidity and mortality of COVID-19. This study aimed to describe the clinical symptoms and risk factors of COVID-19 in cancer patients. In a prospective cross-sectional study, during a year, all cancer patients who underwent chemotherapy and/or targeted therapy in our clinic (Kermanshah, Iran) were followed up in terms of getting COVID-19. We analyzed the effect of tumor features and demographic information on clinical manifestations, survival status, therapeutic outcomes, and severity of the disease COVID-19 in 2 categories of cancer (hematologic and solid cancers). Most of the patients (68%) were in the solid tumor category, including breast cancer (24.4%), colon cancer (22%), and gastric cancer (9.8%). There was a statistically significant difference between 2 categories of cancer in the clinical manifestations: the stage of cancer and survival status ( Thrombocytopenia, anemia, and diarrhea are symptoms that, along with common symptoms such as lung involvement, difficulty breathing, and the need for a ventilator, increase the risk of death in cancer patients with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
During the pandemic of COVID-19, cancer patients have been considered as one high-risk group in the morbidity and mortality of COVID-19. This study aimed to describe the clinical symptoms and risk factors of COVID-19 in cancer patients.
METHOD
METHODS
In a prospective cross-sectional study, during a year, all cancer patients who underwent chemotherapy and/or targeted therapy in our clinic (Kermanshah, Iran) were followed up in terms of getting COVID-19. We analyzed the effect of tumor features and demographic information on clinical manifestations, survival status, therapeutic outcomes, and severity of the disease COVID-19 in 2 categories of cancer (hematologic and solid cancers).
RESULTS
RESULTS
Most of the patients (68%) were in the solid tumor category, including breast cancer (24.4%), colon cancer (22%), and gastric cancer (9.8%). There was a statistically significant difference between 2 categories of cancer in the clinical manifestations: the stage of cancer and survival status (
CONCLUSIONS
CONCLUSIONS
Thrombocytopenia, anemia, and diarrhea are symptoms that, along with common symptoms such as lung involvement, difficulty breathing, and the need for a ventilator, increase the risk of death in cancer patients with COVID-19.
Identifiants
pubmed: 35110966
doi: 10.1177/11795549221074168
pii: 10.1177_11795549221074168
pmc: PMC8801664
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795549221074168Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Cancer Invest. 2022 Jan;40(1):26-34
pubmed: 34634986
Cancers (Basel). 2020 Aug 20;12(9):
pubmed: 32825295
J Infect. 2020 Aug;81(2):318-356
pubmed: 32298677
Eur J Haematol. 2020 Nov;105(5):597-607
pubmed: 32710500
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Int J Clin Oncol. 2020 Sep;25(9):1581-1586
pubmed: 32654049
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Eur J Cancer. 2020 Dec;141:171-184
pubmed: 33161241
Future Microbiol. 2013 Nov;8(11):1431-51
pubmed: 24199802
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Hematol Oncol. 2020 Oct 8;13(1):133
pubmed: 33032660
China CDC Wkly. 2020 May 8;2(19):321-326
pubmed: 34594648
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Respir Med Case Rep. 2020;31:101231
pubmed: 32999856
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Radiology. 2020 Aug;296(2):E119-E120
pubmed: 32228363
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Int J Clin Oncol. 2021 May;26(5):826-834
pubmed: 33486624
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Br J Cancer. 2021 Sep;125(7):939-947
pubmed: 34400804
JCO Glob Oncol. 2021 Feb;7:311-323
pubmed: 33617304
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
Anesth Analg. 2020 Jul;131(1):16-23
pubmed: 32543802
Front Public Health. 2020 Sep 04;8:551889
pubmed: 33014984
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Lancet Haematol. 2020 Oct;7(10):e701-e703
pubmed: 32798474
J Natl Compr Canc Netw. 2020 Jan;18(1):12-22
pubmed: 31910384
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Brain Behav Immun. 2020 Jul;87:18-22
pubmed: 32240762
Endocrine. 2020 May;68(2):253-254
pubmed: 32346814
J Natl Compr Canc Netw. 2020 Nov 3;:1-10
pubmed: 33142266
Cancer Rep (Hoboken). 2021 Oct;4(5):e1378
pubmed: 33742793
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Intervirology. 2016;59(3):163-169
pubmed: 28103598